Trial Profile
A Randomized, Dose-Ranging, Safety and Tolerability Study of NBI-3001 Administered by Continuous Intratumoral Infusion Followed by Surgical Resection in Patients With Recurrent Glioblastoma Multiforme
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2013
Price :
$35
*
At a glance
- Drugs Bizaxofusp (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Neurocrine Biosciences
- 25 Jul 2008 Status changed from active, no longer recruiting to completed.
- 24 Sep 2005 New trial record.